News items New start up Patholyt will bring AI research into pathology diagnostics
21 September 2021

Patholyt is on a mission to accelerate the adoption of artificial intelligence in pathology diagnostics and improve the chances of cancer patients worldwide. Patholyt is a spin-off from Radboudumc, a frontrunner in computational pathology research.

Pathology is pivotal in the diagnostic process of many diseases such as cancer. For more than 100 years, pathologists have been using the optical microscope for tissue examination. The field of pathology is now challenged by the world’s shortage of pathologists, and the growing requirements for efficiency and consistent quality.

A revolution in the field

Recent progress in artificial intelligence, imaging, and high-performance computing has unlocked a revolution in the field: AI-powered Computational Pathology. Patholyt will bring research algorithms into clinical practice to both speed up and improve the quality of pathology diagnostics.


Integrating algorithms

Patholyt aims to democratize the access to high quality pathology diagnostics around the world; and believes that at critical moments the chances of cancer patients can be improved through computational pathology. Patholyt’s AI-powered solutions will be integrated into standard digital pathology workflows, providing assistance to pathologists with a seamless experience.

Diagnostics & life sciences support

Patholyt’s products will focus on clinical diagnostic support for complex diseases such as prostate and breast cancer. The company will also provide solutions for biotech, pharma and diagnostics companies.

World-leading science

Patholyt originates from the group of Jeroen van der Laak, head of the Computational Pathology Group from Radboud University Medical Center (Radboudumc). The group is world-renowned for pioneering AI for large-scale whole-slide image analysis with high-ranking journal publications (e.g., automated grading of prostate cancer), the CAMELYON and PANDA challenges for breast and prostate cancer, and the IMI BIGPICTURE project. Patholyt’s management team consists of Patrick de Boer, Jeroen van der Laak, David Tellez and Wouter Bulten. Katrien Gr├╝nberg, Geert Litjens and Francesco Ciompi are members of the advisory board.

More information

Pieter Lomans


neem contact op

Related news items

1.5 million euro grant for research into earlier recognition of Parkinson's disease

27 October 2021

Researchers aim to improve identification of early symptoms and subtypes of Parkinson's disease with large international study

read more

BRAINMODEL: precision medicine for brain disorders

25 October 2021

A team of researchers from Radboudumc, VU Amsterdam and other institutes is going to look for new and better ways to heal developmental disorders in the brain.

read more

Christian Gilissen appointed professor of Genome Bioinformatics

22 October 2021

Christian Gilissen has been appointed Professor of Genome Bioinformatics at the Radboudumc / Radboud University as of 1 October 2021.

read more

How healthy is James Bond? - A flu to a kill No time to die: the pathogens surrounding secret agent 007

21 October 2021

James Bond made a total of 25 films between 1962 and 2021. In all those films, secret agent 007 washed his hands only twice, even though he often stayed in not so hygienic places with considerable health risks. Radboudumc researchers examined all the health risks in the 47 countries Bond visited.

read more